Abstract
This review focuses on Eating Disorders (ED), the role played by neurotransmitters and peptides in ED phenomena as well as the drugs used in the treatment of these diseases. For ED, we mean a syndrome characterized by persistent alteration of eating behavior and the conditions that cause an insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic, serotoninergic and peptidergic systems. In this respect, while serotonin, dopamine and prostaglandin promote the ingestion of food, by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food ingestion, thus, causing the occurence of ED. The drugs mainly used in the treatment of ED are antidepressants such as selective serotonin reuptake inhibitors and tricyclic antidepressants. Additionally, mood stabilizers (lithium), anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in the treatment of ED.
Keywords: Eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorders
Reviews on Recent Clinical Trials
Title: Recent Clinical Aspects of Eating Disorders
Volume: 4 Issue: 1
Author(s): Anna Capasso, Claudio Petrella and Walter Milano
Affiliation:
Keywords: Eating disorders, anorexia nervosa, bulimia nervosa, binge eating disorders
Abstract: This review focuses on Eating Disorders (ED), the role played by neurotransmitters and peptides in ED phenomena as well as the drugs used in the treatment of these diseases. For ED, we mean a syndrome characterized by persistent alteration of eating behavior and the conditions that cause an insufficient ingestion and/or adsorption of foods. There are three different ED diseases: Anorexia Nervosa (AN), Bulimia Nervosa (BN) and Binge Eating Disorders (BED). ED are complex conditions that arise from a combination of long-standing behavioral, emotional, psychological, interpersonal, and social factors. The neuronal circuits that control the ingestion of food are mainly related to catecholaminergic, serotoninergic and peptidergic systems. In this respect, while serotonin, dopamine and prostaglandin promote the ingestion of food, by contrast, neuropeptide Y, norepinephrine, GABA and opioid peptides inhibit food ingestion, thus, causing the occurence of ED. The drugs mainly used in the treatment of ED are antidepressants such as selective serotonin reuptake inhibitors and tricyclic antidepressants. Additionally, mood stabilizers (lithium), anxiolytics, serotonin and noradrenalin reuptake inhibitors and antipsychotic drugs are often used in the treatment of ED.
Export Options
About this article
Cite this article as:
Capasso Anna, Petrella Claudio and Milano Walter, Recent Clinical Aspects of Eating Disorders, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047594
DOI https://dx.doi.org/10.2174/157488709787047594 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phosphonamide-Based Metalloproteinase Inhibitors: A New Approach to the Development of Safer Metalloproteinase Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Ghrelin and Growth Hormone Secretagogues, Physiological and Pharmacological Aspect
Current Drug Discovery Technologies Dronedarone – A New Alternative for Management of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Cardiovascular Effects of Neuregulin-1/ErbB Signaling: Role in Vascular Signaling and Angiogenesis
Current Pharmaceutical Design Integrin α4β7 Antagonists: Activities, Mechanisms of Action and Therapeutic Prospects
Current Immunology Reviews (Discontinued) Non-Cardiomyocytes in Heart Regeneration
Current Drug Targets Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Oxidative Stress During Myocardial Ischaemia and Heart Failure
Current Pharmaceutical Design Altered Calmodulin Degradation and Signaling in Non-Neuronal Cells from Alzheimer’s Disease Patients
Current Alzheimer Research Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Different Concepts of Drug Delivery in Disease Entities
Mini-Reviews in Medicinal Chemistry Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology Bridging the Gap: The Potential Role of Corticosteroid Binding Globulin in Cardiac Steroid Facilitation
Current Drug Targets Redox State in Atrial Fibrillation Pathogenesis and Relevant Therapeutic Approaches
Current Medicinal Chemistry Radiation-Induced Stress Proteins - the Role of Heat Shock Proteins (HSP) in Anti- Tumor Responses
Current Medicinal Chemistry A New Antihypertensive Agent that Antagonizes the Prohypertensive Effect of Endogenous Ouabain and Adducin
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Peroxidation of Mitochondrial Membrane Phospholipids in Pancreatic β -Cell Failure
Current Diabetes Reviews Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design